학술논문

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Document Type
Abstract
Source
In Blood 5 November 2020 136 Supplement 1:27-28
Subject
Language
ISSN
0006-4971